Table 1.
Variable | p16+/HPV+ N (%) |
p16−/HPV- N (%) |
p-value |
---|---|---|---|
N = 546 (89.4%) | N = 65 (10.6%) | ||
Age | p = 0.84 | ||
< 50 | 86 (15.8) | 11 (16.9) | |
50- < 60 | 231 (42.3) | 25 (38.5) | |
≥ 60 | 229 (41.9) | 29 (44.6) | |
Sex | p < 0.0001* | ||
Male | 473 (86.6) | 44 (67.7) | |
Female | 73 (13.4) | 21 (32.3) | |
Race | p = 0.08 | ||
White | 505 (92.5) | 56 (86.2) | |
Non-white | 41 (7.5) | 9 (13.8) | |
Cancer subsite of origin | p = 0.8 | ||
Base of tongue | 250 (45.8) | 27 (41.5) | |
Tonsil | 252 (46.2) | 26 (40) | |
Other | 44 (8) | 12 (18.5) | |
CCI | p = 0.7 | ||
0 (No comorbidity) | 436 (80) | 49 (75) | |
≥ 1 (At least one comorbidity) | 110 (20) | 16 (25) | |
T-category | p = 0.09 | ||
T1 | 168 (30.8) | 17 (26.2) | |
T2 | 211 (38.6) | 18 (27.6) | |
T3 | 98 (17.9) | 15 (23.1) | |
T4 | 69 (12.7) | 15 (23.1) | |
N-category | p < 0.0001* | ||
N0 | 39 (7.1) | 8 (12.3) | |
N1 | 373 (68.3) | 10 (15.4) | |
N2 | 121 (22.2) | 45 (69.2) | |
N3 | 13 (2.4) | 2 (3.1) | |
AJCC (8th edition) | p < 0.0001* | ||
I | 316 (57.9) | 1 (1.5) | |
II | 149 (27.3) | 4 (6.2) | |
III | 81 (14.8) | 13 (20.0) | |
IV | 0 | 47 (72.3) | |
Smoking status at diagnosis | < 0.0001 | ||
Current smoker | 101 (18.5) | 25 (38.46) | |
Former smoker | 208 (38.1) | 28 (43.08) | |
Never smoker | 249 (40.75) | 12 (18.46) | |
Tobacco exposure (PY) | p < 0.0001* | ||
0 | 277 (50.7) | 13 (20) | |
> 0–10 | 87 (15.9) | 6 (9.2) | |
> 10–20 | 50 (9.2) | 8 (12.3) | |
> 20–30 | 46 (8.4) | 11 (17) | |
> 30 | 86 (15.8) | 27 (41.5) | |
Tobacco exposure per AJCC (8th edition) stage | p < 0.0001 | ||
I/pack-years < 30 | 263 (48.2) | 1 (1.5) | |
I/pack-years ≥30 | 53 (9.7) | 0 | |
II/pack-years < 30 | 113 (20.7) | 1 (1.5) | |
II/pack-years ≥30 | 36 (6.6) | 3 (4.6) | |
III/pack-years < 30 | 59 (10.8) | 4 (6.2) | |
III/pack-years ≥30 | 22 (4) | 9 (13.8) | |
IV/pack-years < 30 | 0 | 27 (41.6) | |
IV/pack-years ≥30 | 0 | 20 (30.8) | |
Chemotherapy (Cth) sequence | p = 0.94 | ||
No Cth | 99 (18.1) | 12 (18.5) | |
Induction Cth (IC) only | 82 (15.0) | 8 (12.2) | |
Concurrent Cth (CC) only | 210 (38.5) | 25 (38.5) | |
IC + CC | 155 (28.4) | 20 (30.8) |
Abbreviations: EBRT external beam radiation therapy, IC induction chemotherapy, CEBRT concurrent chemotherapy + EBRT. * indicates p < 0.05 when comparing the HPV+ and HPV- groups